Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuron taking forward new therapy for fatty liver disease

This article was originally published in Scrip

Executive Summary

The Australian firm Immuron is planning to submit by the end of this year a US IND to begin a multinational Phase IIb trial with a potential treatment for non-alcoholic steatohepatitis (NASH), with the aim of starting enrolment in the first half of 2012.

You may also be interested in...



Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

Post-IPO Zentalis Plows New Ground With China Oncology Venture

US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio. 

Japan To Reimburse Zolgensma – But At Lower Price Than US

Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel